Sign in

You're signed outSign in or to get full access.

David Breslauer

Chief Technology Officer and Chief Product Officer at Bolt Projects Holdings
Executive
Board

About David Breslauer

David Breslauer, 42, is co‑founder of Bolt Threads and serves as Chief Technology Officer, Chief Product Officer, and a director of Bolt Projects Holdings (BSLK). He holds a B.S. in Bioengineering from UC San Diego and a Ph.D. in Bioengineering from UC Berkeley/UCSF, and has served on Bolt’s board since August 2009 . Company operating performance in 2025 shows early commercialization traction: Q2 2025 revenue of $1.3 million with positive gross profit , Q3 2025 revenue of ~$0.4 million and gross margin of 16% , and reported Q3 2025 EBITDA of $(7.2) million and adjusted EBITDA of $(2.5) million .

Past Roles

OrganizationRoleYearsStrategic Impact
Bolt Threads (pre‑Business Combination)Co‑founder; Chief Technology Officer; DirectorSince Aug 2009Led technology and product development in biomaterials; continuity and domain expertise on the board .
Bolt Projects Holdings (post‑Closing)Chief Technology Officer; Chief Product Officer; DirectorSince the Business Combination closingDrives commercialization of Vegan Silk technology; board continuity post‑listing .

External Roles

OrganizationRoleYearsStrategic Impact
Multiple biotechnology companiesAdvisorNot disclosedAdvises companies focused on creating sustainable products; extends network and industry insight .

Fixed Compensation

YearBase Salary ($)All Other Compensation ($)Total ($)
2023286,760 1,933 335,818
2024290,000 10,815 3,467,994

Notes:

  • All other compensation consists of employer matching contributions under Bolt’s 401(k) plan .
  • Bolt does not provide perquisites and does not make tax gross‑ups to executives .

Performance Compensation

Stock Awards (RSUs)

Grant DateShares Granted/OutstandingGrant‑Date Fair Value ($)Vesting TermsLiquidity Condition
2024 RSUs (Outstanding at FY‑end)13,197 unvested 2,801,472 (2024 Stock Awards) One‑sixth vests on each of the 12th–17th monthly anniversaries of Closing, subject to service Satisfied upon Initial Liquidity Event (Business Combination)

Option Awards

Grant DateTypeSharesExercise Price ($)VestingExpiration
11/25/2024Service‑based60,0006.80 Fully vested upon grant 11/25/2034
11/25/2024Service‑based15,9846.80 1/12th quarterly, subject to service 11/25/2034
Legacy options (various)Service/performance2,802 cumulative exercisable/unexercisable counts across older grants87.40–430.00 rangesMonthly vesting schedules; some performance‑milestone options2025–2030

Award Modifications and Repricing (Red Flag)

  • On August 3, 2025, BSLK repriced executive and director options: 282,527 shares (orig. $6.80) and 70,859 shares (orig. $5.90) reset to $2.42 (closing price prior to repricing). Accounted for as a modification with no incremental fair value .

Performance Metrics Tied to Pay

  • Executive RSUs and certain options include service and liquidity/performance‑milestone conditions; the proxy does not disclose revenue/EBITDA/TSR targets or weightings for NEO plans .

Equity Ownership & Alignment

MetricSep 22, 2025Oct 10, 2025
Total Beneficial Ownership (shares)138,096 135,029
Ownership (% of SO)3.6% 3.4%
Direct Shares15,794 15,794
Trust (David N. Breslauer Family Trust)39,167 39,167
Options exercisable within 60 days69,683 71,015
RSUs vesting/vested subject to deferred settlement within 60 days13,452 9,053

Notes:

  • Shares outstanding basis: 3,706,197 (Sep 22, 2025) ; 3,940,170 (Oct 10, 2025) .
  • No disclosure of share pledging or hedging by Mr. Breslauer was identified in the cited filings; company policies reference trading and ownership guidelines but do not enumerate pledging terms in the excerpts reviewed .

Employment Terms

ItemDisclosure
Employment Agreement (2024)Bolt was not party to an employment arrangement with Mr. Breslauer during fiscal 2024 .
Change‑in‑Control & SeveranceCompany maintained a Severance Policy that expired on June 9, 2024; Mr. Breslauer participated. Upon qualifying termination within 12 months of a change‑in‑control: 6 months of base salary lump sum; up to 6 months healthcare; accelerated vesting of 100% of outstanding equity awards (performance awards vest on actual or target if undetermined); subject to release; “best pay cap” for 280G excise tax mitigation; no tax gross‑ups .
Clawback/RecoveryCompensation committee administers and oversees compliance with the compensation recovery policy .

Board Governance and Director Compensation

  • Board service: Mr. Breslauer is an executive officer and director; he does not receive additional compensation for director service (employee directors are excluded from the director pay program) .
  • Committee roles: Current standing committees and membership disclosed; Mr. Breslauer is not listed on the Audit, Compensation, or Nominating & Corporate Governance committees (all independent) .
  • Board leadership: CEO Daniel Widmaier serves as Chair; independent directors appointed a Lead Independent Director (Christine Battist) in August 2025 to mitigate dual‑role concerns through agenda control, executive session leadership, and liaison responsibilities .
  • Audit Committee Chair change: On Aug 18, 2025, Gail Zauder appointed chair (superseding Christine Battist) .
  • Non‑employee director compensation program (context): Annual cash retainer $40,000; chair retainers Audit $15,000, Compensation $12,000, Nominating $8,000; audit committee member retainer $8,000; equity grants include 1,125 RSU initial award (3‑year vest) and 750 RSU annual award (1‑year vest) .

Performance & Track Record

MetricQ2 2025Q3 2025FY 2025 Guidance
Revenue ($ thousands)1,302 ~400 4,500
Gross Margin (%)~5% 16% Gross profit >$1.0M (implied margin uplift)
EBITDA ($ thousands)N/A(7,156) N/A
Adjusted EBITDA ($ thousands)N/A(2,496) N/A

Notes:

  • Company updated Q3 prelims on Oct 21, 2025 (revenue ~370k; GM ≥15%) and reiterated FY 2025 revenue ~$4.5M; gross profit guidance raised to $1.0M .
  • Q3 2025 press release reiterated revenue ~$0.4M, GM 16%, Q4 margin expected >40% .

Compensation Structure Analysis

  • 2024 compensation mix shifted heavily to equity: Stock awards $2,801,472 vs $47,125 in 2023; option awards $365,707 vs none in 2023—raising at‑risk pay alignment but also near‑term dilution and potential supply if vesting accelerates .
  • Option repricing to $2.42 on Aug 3, 2025 materially reduced exercise prices on insider/board awards, a governance red flag indicating willingness to modify underwater grants and potentially increasing future sellable supply as options move in‑the‑money .
  • RSU design emphasizes service and liquidity conditions rather than disclosed financial metrics; the compensation committee oversees recovery policy but no explicit revenue/EBITDA/TSR metrics or weights are disclosed for NEO incentives in 2024 .

Equity Award and Vesting Detail

Award TypeSpecifics
2024 RSUs (13,197 unvested at FY‑end)One‑sixth vests on each of the 12th–17th monthly anniversaries post‑Closing; liquidity condition satisfied at Business Combination .
11/25/2024 Options60,000 fully vested at grant; 15,984 vest 1/12th quarterly; strike $6.80; expire 11/25/2034 .
Legacy optionsMix of service‑based and performance‑milestone‑based schedules across 2015–2021 grants; high strikes ($87.40–$430.00) and monthly vesting mechanics .

Employment & Retention Risk Signals

  • No formal employment agreement in 2024 (contractual protections limited to the expired Severance Policy), indicating reliance on equity awards and ongoing role fit for retention .
  • Repricing and fully vested 60,000 options (Nov 2024) could add near‑term selling optionality, depending on liquidity and price levels; RSU cadence provides staggered settlement that may moderate supply .
  • Clawback oversight exists; no perquisites or tax gross‑ups reported, signaling shareholder‑friendly posture on ancillary pay .

Governance, Voting, and Independence Context

  • Board elected Breslauer and other Class I directors at the Aug 29, 2025 Annual Meeting; strong “FOR” votes (~1,003k for Breslauer) suggest investor support .
  • CEO/Chair dual‑role retained, with Lead Independent Director installed to enhance oversight and independent director coordination .
  • Independent committee membership across Audit, Compensation, and Nominating; committee charters and independence standards disclosed .

Investment Implications

  • Alignment: Breslauer’s 3.4% beneficial ownership, including direct, trust, and near‑term exercisable options/settling RSUs, aligns incentives with equity holders and provides continuity in technical leadership .
  • Supply risk: The Aug 2025 option repricing and fully vested Nov 2024 options increase potential insider liquidity over time; monitor Form 4 activity and vesting calendars for selling pressure signals .
  • Retention: Absence of a current employment agreement and the expiration of the Severance Policy shift retention reliance to ongoing role fit and equity; staggered RSU vesting supports retention but reduces hard severance protections .
  • Governance: CEO/Chair dual‑role remains, but a Lead Independent Director and independent committees mitigate independence concerns; Breslauer’s executive‑director dual role is balanced by non‑employee director committee oversight .
  • Execution: Revenue ramp and margin improvements demonstrate traction, but EBITDA and adjusted EBITDA remain negative; delivering FY 2025 guidance and margin targets is key to validating pay‑for‑performance and de‑risking equity compensation overhang .
Citations: **[1841125_0001213900-25-092437_ea0258133-s1_bolt.htm:93]** **[1841125_0001213900-25-080008_ea0254003-s1_bolt.htm:47]** **[1841125_0001841125-25-000154_bolt-ex991xq325earningspre.htm:0]** **[1841125_848a7bffd34e4e35aa60270d10d18982_0]** **[1841125_0001841125-25-000154_bolt-ex991xq325earningspre.htm:8]** **[1841125_848a7bffd34e4e35aa60270d10d18982_11]** **[1841125_0001841125-25-000085_bslk-20250718.htm:37]** **[1841125_0001213900-25-092437_ea0258133-s1_bolt.htm:100]** **[1841125_0001213900-25-080008_ea0254003-s1_bolt.htm:91]** **[1841125_0001213900-25-092437_ea0258133-s1_bolt.htm:104]** **[1841125_0001841125-25-000155_bslk-20250930.htm:34]** **[1841125_0001841125-25-000148_boltthreadsincdefinitivepr.htm:11]** **[1841125_0001213900-25-092437_ea0258133-s1_bolt.htm:90]** **[1841125_0001841125-25-000142_bslk-amendedandrestatedbyl.htm:12]** **[1841125_0001213900-25-092437_ea0258133-s1_bolt.htm:105]** **[1841125_0001213900-25-080008_ea0254003-s1_bolt.htm:88]** **[1841125_0001841125-25-000085_bslk-20250718.htm:27]** **[1841125_0001841125-25-000120_boltthreadsincproxysupplem.htm:2]** **[1841125_0001841125-25-000122_bslk-20250829.htm:1]**